← Back to headlines
Novartis Faces Drug Pipeline Scrutiny Amid Valuation Premium Focus
Pharmaceutical giant Novartis is under pressure to prove the strength of its drug pipeline as its valuation premium comes under investor focus.
20 Jul, 05:07 — 20 Jul, 05:07
Sources
Showing 1 of 1 sources
